hotspot -WSS

hotspot

author：leisure time 2025-10-01 20:15:12 - browse：963

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Head of FDA's diagnostics center, who led through Covid, retires

WSS

CVS is on a mission to consolidate health care. Will it work?

Immune cells and nerve overgrowth may explain recurring UTI pain

Stem cell biologist probes earliest stages of human development

Longer MASH drug regimen improved liver, Akero study finds

A new approach to psychiatric drug development

Harvard's David Sinclair gets blowback over aging

focus

hotspot

entertainment

At least 13 dead in Texas as scorching temps continue

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

In Memoriam: Notable people who died in 2023

The untold story of TV’s first prescription drug ad

Wildfire smoke exposes gaps in outdoor worker protections

High breast density mammograms need follow

How one medical school became remarkably diverse

Inaction leaves children at risk from dangerous chemotherapy drug

ChatGPT in medicine: STAT answers readers' burning questions

A new approach to psychiatric drug development

explore

Immunocompromised patients offer clues on chronic Covid

The public health thinking behind the CDC’s new Covid guidance

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Mass General, Mayo Clinic look to monetize custom

The untold story of TV’s first prescription drug ad

Immunocompromised patients offer clues on chronic Covid

focus

hotspot

hotspot

hotspot